Fig. 4From: Clinical application of the AUC-guided dosage adjustment of docetaxel-based chemotherapy for patients with solid tumours: a single centre, prospective and randomised control studyThree-year survival rate of patients receiving BSA-guided dosage adjustment versus PK-guided dosage adjustment. The difference between the two groups was significant (67.8% in the PK group vs. 39.0% in the BSA group, P = 0.034)Back to article page